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Background: 53BP1 binds to the tumor suppressor p53 and has a key role in DNA damage response and repair.
Low 53BP1 expression has been associated with decreased survival in breast cancer and has been shown to
interact with several prognostic factors in non-small cell lung cancer. The role of 53BP1 in pancreatic ductal
adenocarcinoma (PDAC) has yet to be determined. We aimed to investigate whether 53BP1 levels interact with
established prognostic factors in PDAC.
Methods: 106 patients for whom there was tissue available at time of surgical resection for PDAC were included. A
tissue microarray was constructed using surgical specimens, stained with antibodies to 53BP1, and scored for
expression intensity. Univariate and multivariate statistical analyses were performed to investigate the association
between 53BP1 and patient survival with known prognostic factors for survival.
Results: The association of 53BP1 with several established prognostic factors was examined, including stage, tumor
grade, surgical margin, peripancreatic extension, lymph node ratio (LNR), and CA 19–9. We found that 53BP1
modified the effects of known prognostic variables including LNR and CA 19–9 on survival outcomes. When 53BP1
intensity was low, increased LNR was associated with decreased OS (HR 4.84, 95% CI (2.26, 10.37), p<0.001) and high
CA19-9 was associated with decreased OS (HR 1.72, 95% CI (1.18, 2.51), p=0.005). When 53BP1 intensity was high,
LNR and CA19-9 were no longer associated with OS (p=0.958 and p=0.606, respectively).
Conclusions: In this study, 53BP1, a key player in DNA damage response and repair, was found to modify the
prognostic value of two established prognostic factors, LNR and CA 19–9, suggesting 53BP1 may alter tumor
behavior and ultimately impact how we interpret the value of other prognostic factors.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer death in the United States and
continues to have a dismal prognosis, with a 5-year over-
all survival rate less than 4% [1]. The only potential
curative option is surgical resection, for which less than
20% of patients are eligible. Even in this subset of pa-
tients, the 5-year overall survival remains only 18–24%
[2-6]. Given the poor survival with surgery alone,* Correspondence: fen.xia@osumc.edu
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reproduction in any medium, provided the orattempts have been made to improve outcomes with ad-
juvant therapy. In multiple retrospective studies,
chemoradiation therapy has been shown to confer a sur-
vival advantage compared with surgical resection alone
[2,7,8]. Other studies suggest a benefit to adjuvant
chemotherapy alone and not to adjuvant chemoradiation
therapy [9-11]. The role of adjuvant therapy in the man-
agement of localized pancreatic cancer remains contro-
versial as many of the randomized clinical trials were
statistically underpowered and used outdated radiation
fractionation schema and techniques. Therefore, tumor
biomarkers that could be used to predict which subset
of patients is likely to benefit from adjuvant therapyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that individual patient’s tumor characteristics.
Many chemotherapeutic agents act by inducing DNA
damage within rapidly dividing tumor cells. Ionizing radi-
ation also causes DNA damage by inducing double-strand
breaks (DSBs), which results in cell death. Molecular tar-
gets that regulate DNA damage and repair are hence likely
to be good predictors of prognosis and response to treat-
ment. The p53 binding protein 1 (53BP1) is a key medi-
ator of DNA damage response, as it is a critical transducer
of the DNA damage signal to p53 and other tumor sup-
pressors [12]. DNA DSBs are typically repaired by two
major pathways: template-based homologous recombin-
ation (HR) and nontemplate-based nonhomologous end
joining (NHEJ) [13]. 53BP1 plays a key role in promoting
the use of NHEJ to repair lethal DSBs [14]. Poly-(ADP-
ribose) polymerase (PARP) is a key nuclear enzyme in
DNA single-strand break repair whose inhibition induces
synthetic lethality in BRCA1-mutated tumor cells which
are HR deficient [15,16]. DNA double-strand breaks in
BRCA1Δ11/Δ11 cells, which are deficient in HR, are aber-
rantly joined by NHEJ dependent on 53BP1 [17]. Interest-
ingly, deletion of 53BP1 in BRCA1Δ11/Δ11 cells restored
HR and alleviated hypersensitivity of BRCA1-mutated cells
to PARP inhibition, rendering BRCA1Δ11/Δ11 cells insensi-
tive to PARP inhibition [17]. In another study, Bouwman
et al. found that 53BP1 deletion reversed cisplatin sensitiv-
ity induced by BRCA1 inactivation [18]. Thus, 53BP1 ex-
pression may be a good predictor of pancreatic tumor
response to DNA damage-based therapy.
Additionally, low 53BP1 expression has been shown to
be associated with poor prognosis. Bouman et al. found
that loss of 53BP1 was associated with poor prognosis in
patients with triple-negative breast cancer [18]. The role
of 53BP1 in PDAC is yet to be determined. In this study,
we investigate whether 53BP1 protein expression level is
associated with pancreatic tumor behavior and how it in-
teracts with other established prognostic factors in PDAC.
Methods
Patient selection and data collection
This study was approved by the Vanderbilt University
Medical Center Institutional Review Board. 106 patients
were identified who had undergone curative resections
for pancreatic adenocarcinoma and for whom both clin-
ical data and tumor tissue were available. Only patients
with histologically confirmed ductal adenocarcinomas
were included. All tumors were restaged by a single
pathologist (SCW) according to AJCC 7th edition criteria
[19]. Data collected included patient demographics, op-
erative details, treatment details and survival. Pathologic
data obtained included tumor location, total number of
nodes involved, total number of nodes resected, tumor
size, differentiation, pancreatic extension, and marginstatus. A positive margin was defined as tumor within 1
mm of the inked resection margin on microscopic exam-
ination. The assessment of margins and slicing techniques
were performed in a standardized fashion for all patients
as previously described [20]. Tumor differentiation was
recorded according to the guidelines outlined by the Col-
lege of American Pathologists [21]. The lymph node ratio
(LNR) was defined as the number of positive lymph nodes
as a fraction of the total number of lymph nodes exam-
ined. CA 19–9 level was determined by a quantitative
electrochemiluminescent immunoassay (Roche Modular
E170) with a reference interval of 0–37 U/mL.
Construction of tissue microarray
Tissue microarrays were constructed using 1 mm cores
of both tumor and background normal/reactive pan-
creas from 106 curative resection specimens, including
pancreaticoduodenectomy/gastrojejunostomy procedures
(Whipple procedures) and total or distal pancreatecto-
mies. The microarrays were composed of single or dupli-
cate cores from tumor and background pancreas. The
microarrays were cut at 5 μm-thickness and stained with
hematoxylin and eosin.
Immunohistochemistry study
5 μm-thick sections of formalin-fixed, paraffin-embedded
tissue microarrays were de-paraffinized and rehydrated.
Samples were pretreated to promote antigen retrieval with
Target Retrieval Solution (DAKO, Carpinteria, CA, USA).
Sections were blocked with 3% hydrogen peroxide, followed
by blocking in 2% goat serum/0.1% Triton-X 100/PBS
(1 hour). Slides were then incubated with primary antibody
53BP1 (1:200 dilution in blocking buffer, NOVUS, Cat.
No. NB100-304) overnight at 4°C. Slides were washed
in phosphate-buffered saline. DAB (3,3-diaminobenzidine
tetrahydrochloride dehydrate, Invitrogen, Cat. No. 00–
2020) was applied. 53BP1 expression was analyzed by
microscopy (Carl Zeiss, Thornwood, NY).
Positive and negative controls were established with the
use of human breast cancer cells and a human breast
tumor specimen. The MCF-7 cell line, which is derived
from human breast cancer and expresses 53BP1 as con-
firmed by us and other research laboratories [22], was first
used to perform 53BP1 antibody immunostaining. The
MCF7 cells were not paraffin imbedded and were instead
cultured as a monolayer in a tissue culture chamber prior
to immunostaining. For a positive control, cells were
stained with antibody to 53BP1 as described above. For a
negative control, the primary antibody was not used and
instead was replaced by non-immune rabbit IgG at the
same concentration of the primary antibody. We obtained
positive staining in the positive control and negative stain-
ing in the negative control. Next, 53BP1 immunostaining
was performed in a human cancer tumor specimen. A
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tumors have been reported to have positive 53BP1 expres-
sion [23,24]. 5 μm-thick consecutive sections of formalin-
fixed, paraffin-embedded breast cancer tissue were de-
paraffinized and rehydrated as described above. Tissue was
stained with antibody to 53BP1. For a negative control, a
consecutive section from the same specimen was not
stained with the primary 53BP1 antibody and instead was
replaced by non-immune rabbit IgG at the same concentra-
tion of the primary antibody. The immune-staining specifi-
city of the 53BP1 antibody was confirmed by no staining in
the negative control which omitted the primary 53BP1 anti-
body and positive staining in the specimen to which the
primary antibody was applied. For each pancreatic cancer
tissue microarray, a total of 300–450 cells were counted.
The intensity of staining was scored as 1+ (weakly staining/
least intense), 2+ (moderately staining), or 3+ (strongly
staining/most intense) in tumor cells. Due to limited sam-
ple size, 1+ and 2+ staining intensity were grouped into
“low” intensity, and 3+ staining intensity was referred to as
“high” intensity. Stromal cells were not included in the
scoring. Assessment of 53BP1 staining was performed by a
single person blinded to patient outcomes. Representative
immunohistochemical staining is shown in Figure 1.
Statistical analysis
The primary endpoint was defined as the time from
surgery to the date of all-cause death (overall survival,Figure 1 Representative immunohistochemistry staining for 53BP1 ex
53BP1 expression and (B) is low intensity of 53BP1 expression.OS) or last follow-up. The secondary endpoint was
defined as the time from surgery to the date of disease
recurrence (recurrence-free survival, RFS) or last follow-
up. Patients’ demographic and clinical variables were
summarized using the median with the 25th and 75th
percentiles (interquartile range, IQR) for continuous var-
iables. For categorical variables, frequency and percent-
ages were shown. The Wilcoxon rank sum test was used
for continuous variables, and Pearson’s χ2 or Fisher’s
exact test was used to compare categorical variables
between 53BP1 intensity groups (low or high). The
Kaplan-Meier method, Log-rank test, likelihood ratio
test, and Cox proportional hazard (Cox PH) models
were used in univariate and multivariate analysis when
appropriate to investigate the associations between the
endpoints and the risk factors. Predetermined interac-
tions of 53BP1 levels by LNR and 53BP1 levels by CA
19–9 levels were included in all multivariable models.
All statistical inferences were assessed at a two-sided 5%
significant level and all summary statistics, graphics, and
survival models were generated using R version 2.13
statistical software [25].
Results
Patient clinical and pathologic characteristics
106 patients were identified who had undergone curative
resections for PDAC for whom tissue samples were also
available for study. Table 1 summarizes the demographicpression in pancreatic adenocarcinoma. (A) is high intensity of
Table 1 Patient clinical and pathologic characteristics
N No. (%)














Tumor size 106 3.0 (2.1–3.5) a
Lymph node status (N stage) 104
N0 35 (34)
N1 69 (66)
Number of resected nodes 104 11.0 (8.0–18.2) a
Number of positive nodes 104 1.0 (0.0–4.0) a
Lymph node ratio 104 0.095 (0.000–0.257) a
Operation type 106
Whipple 93 (87.7)
Distal pancreatectomy 9 (8.5)
Total pancreatectomy 3 (2.8)
En bloc resection 1 (1)






Adjuvant radiation therapy 102
No 50 (49)
Yes 52 (51)
CA 19-9 106 157 (50–520) a
53BP1 expression intensity 106
Low intensity 62 (58)
High intensity 44 (42)
Overall survival status 106
Alive 23 (22)
Deceased 83 (78)
Survival time, months 106 15.5 (8.2–35.4) a
a: median (IQR).
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ings. Of the 106 patients undergoing surgical resection,
71.0% had microscopically negative surgical margins.
The median OS for all patients was 15.5 (IQR: 8.2–35.4)
months.
Univariate analysis
53BP1 staining intensity was not found to be associated
with OS or RFS (p>0.05). 53BP1 intensity was not found
to be associated with tumor stage, tumor grade, adjuvant
chemotherapy use, CA 19–9 level, or LNR (p>0.05).
Findings are summarized in Table 2.
Multivariable analysis
Recent molecular correlative studies in glioblastoma
have shown that certain molecules can modify the value
of other prognostic biomarkers [26]. Although 53BP1 in-
tensity was not associated with any of the known prog-
nostic factors in univariate analysis, we postulated that
53BP1 expression levels could interact with and thereby
modify established prognostic markers in PDAC. Lymph
node involvement in PDAC predicts for worse survival.
Carbohydrate 19–9 antigen (CA 19–9) is a sensitive and
specific biomarker for pancreatic cancer. The total CA
19–9 values as well as the rates of decline have been
shown to predict survival in patients with advanced dis-
ease [27-31].
In multivariable analysis, we observed that 53BP1 in-
tensity modifies the prognostic ability of both LNR and
CA19-9. When 53BP1 intensity is low, increased LNR
was associated with decreased OS (HR 4.84, 95% CI
(2.26, 10.37), p<0.001) and high CA19-9 was associated
with decreased OS (1.72, (1.18, 2.51), p=0.005). When






Tumor grade 0.85 a
1 8 (13%) 7 (16%)
2 36 (58%) 26 (59%)
3 18 (29%) 11 (25%)
Tumor stage 0.98 a
I-IIA 18 (29%) 13 (30%)
IIB-IV 44 (71%) 31 (70%)
Adjuvant chemotherapy 1 a
No 16 (27%) 11 (26%)
Yes 44 (73%) 31 (74%)
CA 19-9 210 (66–660) 1 112 (32–337)1 0.12 b
Lymph node ratio 0.10 (0.00–0.25) 1 0.09 (0.00–0.27) 1 0.92 b
a: Fisher’s Exact Test.
b: Wilcoxon Rank Sum Test.
1: Median (IQR).
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When 53BP1 intensity was low, increased LNR was also
associated with decreased RFS (3.92, (1.79, 8.58),
p<0.001) and high CA 19–9 had a trend towards de-
creased RFS that did not reach statistical significance
(1.38, (0.97, 1.96), p=0.077). Results are summarized in
Table 3. Hazards ratios are shown in Figure 2.
Discussion
In this study, 53BP1 was found to modify the effect of
two established pancreatic cancer clinicopathological
prognostic factors, LNR and CA 19–9 level, on patient
survival.
The number of nodes involved is a function not only
of the rates of true node positivity but also of the aggres-
siveness of the surgeon in obtaining these nodes and the
pathologist in finding these nodes at the time of resec-
tion. Adequate staging of node negative pancreatic can-
cer requires the evaluation of at least 12 nodes.
Unfortunately, this is not always feasible. The ratio of
number of positive nodes to the number of nodes exam-
ined or the LNR help to equalize these variations in both
surgical technique as well as pathological nodal evalu-
ation. LNR has been shown to be of prognostic value in
a variety of gastrointestinal tumors including cancers of
the stomach, esophagus, colon, rectum, and biliary tract
[32-36] and has been suggested as an important prog-
nostic factor in pancreatic cancer as well [37-40]. How-
ever, the current determination of N stage in pancreatic
cancer is delineated as either positive or negative, rather
than the absolute number of nodes or LNR. In our
study, we found that when 53BP1 intensity was low,Table 3 Multivariable Cox PH analyses for OS and RFS
Overall survival
Variables HR 95% CI
Age at surgery 1, a 1.27 0.84–1.91
Lymph node ratio
Within High 53BP1 level strata 2, a 0.98 0.43–2.22
Within Low 53BP1 level strata 2, a 4.84 2.26–10.37
CA19-9
Within High 53BP1 level strata 3, a 0.87 0.52–1.47
Within Low 53BP1 level strata 3, a 1.72 1.18–2.51
Adjuvant chemotherapy: Yes 0.34 0.19–0.60
Margin Positive 2.37 1.35–4.14
Peripancreatic extension status Positive 2.29 1.12–4.65
Perineural invasion status Positive 0.52 0.29–0.95
a: upper quartile vs. lower quartile.
b: P value for interaction terms with 53BP1 Level.
1: 73.10 vs. 58.38.
2: 25.69% vs. 0%.
3: 519.75 vs. 50.
*: statistically significant.increased LNR was associated with decreased OS (HR
4.84, p<0.001) and RFS (HR 3.92, p<0.001). However, the
association of LNR with survival was lost when 53BP1
intensity was high, suggesting that 53BP1 may modulate
the tumor cellular environment where low 53BP1 ex-
pression level causes worse prognosis for high LNR.
CA 19–9, a sialylated Lewis (Lea) antigen of the
MUC1 protein, is another prognostic marker in pancre-
atic cancer, and serial measurements of CA 19–9 have
been shown to be useful to monitor treatment response
[41,42]. There are several studies that have evaluated CA
19–9 as a pretreatment prognostic marker [27-31], and
although there is no established threshold value for
prognostic evaluation, 370 U/ml has been found to div-
ide patients into two groups with a significant difference
in survival [43]. In our study, we found that when 53BP1
intensity was low, high CA19-9 was associated with de-
creased OS (HR 1.72, p=0.005). When 53BP1 intensity
was high, CA 19–9 was no longer associated with overall
survival.
Taken together, our results suggest 53BP1 expression
levels may precondition the tumor cell biological behavior.
53BP1, as a DNA damage response protein, is thought to
promote NHEJ and suppress HR [14]. Increased 53BP1
levels therefore likely allows efficient cellular repair of en-
dogenous DNA damage in response to metabolic stress or
chemotherapy and radiation therapy; however, when
53BP1 levels are decreased, there is decreased NHEJ effi-
ciency to repair DNA damage. Our data suggest that low
53BP1 expression may predispose pancreatic tumor cells
to become more vulnerable to changes of intrinsic meta-
bolic stress, tumor microenvironment, and genotoxicRecurrence free survival
p value HR 95% CI p value
0.255 1.00 0.67–1.48 0.982
0.007 b,* 1.02 0.020 b,*
0.958 3.92 0.45–2.29 0.963
<0.001* 1.79–8.58 <0.001*
0.040 b,* 0.226 b
0.606 0.94 0.56–1.57 0.803
0.005* 1.38 0.97–1.96 0.077
<0.001* 0.55 0.30–1.00 0.051
0.003* 1.36 0.75–2.47 0.316
0.022* 2.41 1.16–5.01 0.019*
0.033* 0.46 0.25–0.81 0.008*
Hazard Ratios
Peripancreatic extension status Positive
Perineural invasion status Positive
Margin status Positive
Chemotherapy Yes
CA19 9 in high 53BP1 strata(519.75 vs. 50.00)
Lymph node ratio in high 53BP1 strata(0.26 vs. 0.00)
CA19 9 in low 53BP1 strata(519.75 vs. 50.00)
Lymph node ratio in low 53BP1 strata(0.26 vs. 0.00)
Age at surgery(73.10 vs. 58.38)
0 2 4 6 8 10
Hazard Ratios
Peripancreatic extension status Positive
Perineural invasion status Positive
Margin status Positive
Chemotherapy Yes
CA19 9 in high 53BP1 strata(519.75 vs. 50.00)
Lymph node ratio in high 53BP1 strata(0.26 vs. 0.00)
CA19 9 in low 53BP1 strata(519.75 vs. 50.00)
Lymph node ratio in low 53BP1 strata(0.26 vs. 0.00)
Age at surgery(73.10 vs. 58.38)
0 2 4 6 8
A. 
B. 
Figure 2 Hazard ratios for clinical and pathologic characteristics for (A) OS and (B) RFS.
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modify how other prognostic factors such as LNR and
CA19-9 predict overall survival.
In a cohort of breast cancer patients treated with
breast-conserving surgery and radiotherapy, low 53BP1
was associated with worse clinical outcomes including
recurrence-free survival, distant metastasis-free survival,
and overall survival [24]. Bouman et al. found that 53BP1
loss was associated with the poor prognosis triple-negative
breast cancers [18]. 90.5% of breast tumors that were defi-
cient in 53BP1 were triple-negative. Of the triple-negative
tumors assayed, 43% were 53BP1 negative and in non-triple-
negative tumors, only 2% were 53BP1 negative (p<0.0001).
Together, this data suggests 53BP1 loss is more frequent in
more aggressive breast cancers. While in our study low
53BP1 was not directly associated with overall survival,
low 53BP1 expression modified the prognostic value of CA
19–9 and LNR so that high CA 19–9 and high LNR wereassociated with worse OS. With high 53BP1, LNR and CA
19–9 were no longer associated with overall survival. One
study has shown an association between 53BP1 and
established lung cancer prognostic factors, such as smoking
status, lymphovascular invasion, and tumor stage [44].
Due to study size limitation, our study was unable to
test whether 53BP1 could modify the effects of other
clinicopathological factors such as adjuvant chemother-
apy, margin status, peripancreatic extension status, and
perineural invasion status. For example, based on the
biologic function of 53BP1, 53BP1 may modify the prog-
nostic value of adjuvant chemotherapy such as the use
of PARP inhibitors due to the ability of 53BP1 to alter
homologous recombination (HR) and nonhomologous
end joining (NHEJ). Loss of this protein may result in
the inability of cells to repair damaged DNA and modify
sensitivity to chemotherapeutic agents. Also, an import-
ant question not addressed in our study that should be
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any of the clinicopathologic factors and local recurrence
or distant metastasis.
There are several limitations to our study. For in-
stance, our study group is heterogenous in that patients
were included regardless of type of surgical procedure,
and the number of lymph nodes retrieved may vary con-
siderably among those procedures. In order to increase
our sample size all patients were included. Additionally,
in our study perineural invasion was found to have a
positive impact on survival, which is inconsistent with
the literature. Our finding may be the result of small
numbers and the retrospective nature of tissue collec-
tion. Our study found that CA 19–9, positive margin,
and adjuvant chemotherapy were associated with OS but
not RFS. The lack of association with RFS may be a
function of the difficulty of accurately coding of recur-
rence in a retrospective study that spanned such a long
time period. Therefore, our hypothesis should be tested
with prospectively collected tissue in a large cooperative
group setting.
Future studies are warranted to further characterize
the role of 53BP1 in PDAC as well as to study the mech-
anisms by which 53BP1 intensity affects tumor cell be-
havior. Our results point to the complexity of the
translation of cancer cell biology to clinical tumor be-
havior. A hallmark of cancer cells is the possession of
multiple gene mutations and aberrations in cell signaling
pathways. The ability to identify a single biomarker to
predict tumor response has been disappointing. There
will always be an interaction with additional biomarkers
or clinicopathological factors. Therefore, it is necessary
to interpret the predictive value of a particular bio-
marker in light of the status of other biomarkers in that
individual tumor. Stratification of tumors based on the
summation of several biomarkers and clinicopathological
factors will allow for better predictive value in the clinic.
As the role of 53BP1 in tumors has been shown in sev-
eral studies to modify the sensitivity of BRCA-mutated
cells to chemotherapeutic agents (PARP inhibitors, cis-
platin) [17,18], future studies examining the role of
53BP1 in BRCA-mutated pancreatic cancer would be of
clinical value.
Conclusion
In summary, our results demonstrate 53BP1 modifies
the effect of two established pancreatic prognostic fac-
tors, LNR and CA 19–9, suggesting 53BP1 may alter
tumor behavior and ultimately impact how we interpret
the clinical value of other prognostic factors.
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